Furthermore, we hypothesize that the upregulated cyclin E activity in trastuzumab resistant HER2 positive breast cancer facilitates CDK2 mediated non-canonical Smad3 phosphorylation, resulting in cell cycle progression and oncogenesis. The gene discussed is ERBB2; the disease is breast cancer.